Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
The Californer/10347455

LAS VEGAS - Californer -- Cardiff Lexington Corporation (Stock Symbol: CDIX) $CDIX is continuing to execute an aggressive healthcare expansion strategy focused on some of the most resilient and high-demand sectors in medicine: orthopedics, spine care, pain management, and specialty procedural services.

Through its flagship subsidiary Nova Ortho and Spine, the company has built a growing regional healthcare platform operating throughout Florida and Georgia, targeting underserved patient populations while simultaneously improving profitability, expanding margins, strengthening infrastructure, and advancing its broader capital markets strategy.

With strong financial growth, new healthcare hires, expanding procedural capabilities, and a recent upgrade to the OTCQX Best Market, Cardiff Lexington appears increasingly focused on positioning itself for long-term institutional visibility and scalable healthcare consolidation growth.

Strong Financial Momentum Continues to Validate the Business Model

Cardiff Lexington has continued producing substantial operational growth as Nova Ortho and Spine expands across the Southeast.

Recent company-reported financial results showed:

• Q3 revenue growth of 125.6% year-over-year to $3.1 million
• Gross profit growth of 437.8% to $1.9 million
• Gross margins expanding to 62.4%
• Operating profitability improving significantly
• Fiscal year 2025 revenue increasing 39.5% to $11.5 million
• Fiscal year 2025 gross profit climbing 62.7% to $7.2 million
• Total assets increasing to approximately $29.1 million

The company has now reported multiple consecutive quarters of adjusted EBITDA profitability while continuing to expand geographically and operationally.

For many investors following emerging healthcare operators, the combination of accelerating revenue growth and expanding margins is often viewed as one of the clearest signs that operational leverage is beginning to take hold.

Nova Ortho and Spine Continues Expanding Regional Presence

All current Cardiff Lexington revenue is derived from Nova Ortho and Spine, which operates a growing network of orthopedic, spine, surgical, and pain management facilities across Florida and Georgia.

The company's strategy focuses on:

• Building and acquiring middle-market healthcare clinics
• Expanding orthopedic and spine care access
• Increasing procedural and surgical capabilities
• Serving underserved and rural healthcare markets
• Growing ancillary diagnostic and specialty service revenue streams

Nova Ortho and Spine facilities provide:

• Orthopedic evaluations
• Spine care services
• Interventional pain management
• Surgical coordination
• Specialty consultations
• Diagnostic and imaging support

Management believes these high-demand medical specialties benefit from long-term demographic trends including aging populations, persistent injury-related demand, and recurring insurance-reimbursed procedural revenue.

More on The Californer

• XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
• California: Governor Newsom advocates for disaster recovery and stronger crisis response in Washington, D.C.
• California: Trump sticks Taxpayers with $111 million bill for his illegal deployment of the National Guard in Los Angeles last year
• Long Beach: Vote Centers Open This Weekend for the June 2 Primary Election
• Blue Planet – Red Tide Debuts Amid Super El Niño and UAP Disclosure Headlines

Expansion Into Underserved Florida Markets Creates Additional Growth Opportunities

One of the company's more notable recent operational developments involved Nova Ortho and Spine performing its first procedures at Doctor's Memorial Hospital in Perry, Florida.

Management stated the expansion supports Cardiff Lexington's broader mission of bringing advanced orthopedic and spinal care to underserved and rural patient populations throughout Florida.

According to CEO Alex Cunningham, the company was able to mobilize quickly and deploy procedural services into Taylor County where specialty healthcare access had historically been limited.

This expansion strategy may provide multiple advantages simultaneously:

• Additional geographic revenue growth
• Greater patient reach
• Increased procedural capacity
• Stronger regional healthcare relationships

Strategic Healthcare Hiring Supports Increasing Patient Demand

Cardiff Lexington also recently expanded Nova Ortho and Spine's Florida medical operations through the addition of experienced nurse practitioners with backgrounds in orthopedic surgery, neurosurgery, emergency medicine, and pain management.

The additions are expected to support:

• Growing patient volumes
• Higher procedural throughput
• Expanded clinical capabilities
• Improved operational scalability
• Enhanced patient care efficiency

As healthcare operators continue facing staffing shortages nationwide, experienced procedural medical hires can represent a significant operational advantage for growing specialty healthcare platforms.

OTCQX Upgrade Strengthens Capital Markets Positioning

In April 2026, Cardiff Lexington announced its official upgrade to the OTCQX Best Market, representing another major step in the company's evolving capital markets strategy.

Management stated the OTCQX upgrade reflects the maturation of the company's business operations while strengthening its positioning for future strategic financing and potential uplisting opportunities.

The company has also:

• Filed an S-1 registration statement previously tied to a Nasdaq uplisting initiative
• Engaged investment banking and advisory support
• Continued enhancing corporate governance and reporting infrastructure
• Streamlined portions of its capital structure

While the company recently withdrew a prior registration statement filing, management continues emphasizing long-term strategic capital markets objectives and disciplined growth execution.

More on The Californer

• Governor Newsom announces common signs of "California Derangement Syndrome" — and highlights easy cures
• MoneyDNA app. Learn Why You Spend and Build Better Money Habits
• A Living History Masterclass:102-Year-Old Tule Lake Survivor Jim Tanimoto to Speak in Chico This Sat
• Column Argues Pope's Forthcoming AI Encyclical Is a Battle for Humanity's Future
• Lick Introduces Pineapple Flavored Massage Oil — A Tropical Date Night Favorite Available on Amazon

For emerging healthcare growth companies, improving exchange quality and strengthening public-market visibility can often enhance liquidity, investor awareness, and institutional credibility.

Why Investors Are Watching CDIX

Cardiff Lexington is increasingly attracting attention because it combines several characteristics often sought in emerging healthcare growth companies:

✔ Rapid revenue growth
✔ Expanding gross margins
✔ Multi-quarter profitability improvements
✔ Growing regional healthcare footprint
✔ High-demand specialty medical focus
✔ Rural and underserved market penetration
✔ Strengthening capital markets positioning
✔ Scalable healthcare consolidation strategy

Few micro-cap healthcare operators demonstrate simultaneous growth across financial performance, operational expansion, clinical infrastructure, and market positioning at the pace Cardiff Lexington has recently reported.

The Bottom Line

Cardiff Lexington Corporation $CDIX continues executing a broad healthcare growth strategy centered around orthopedic, spine, and pain management services through its Nova Ortho and Spine platform.

With expanding revenues, improving profitability, growing procedural capacity, continued geographic expansion, and enhanced public-market positioning through its OTCQX upgrade, the company appears focused on building a scalable specialty healthcare platform capable of significant long-term regional growth.

As healthcare fragmentation continues and demand for specialty procedural care rises throughout the United States, Cardiff Lexington may remain a company many growth-oriented healthcare investors continue monitoring closely.

For more information on CDIX visit: https://cardifflexington.com/

Media Contact:
Company Name: Cardiff Lexington Corporation (Stock Symbol: CDIX)
Contact: Alex Cunningham, CEO
Email:  investorsrelations@cardifflexington.com
Phone: (800) 628-2100 ext. 705
Country: United States
Website:  https://cardifflexington.com/

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website